Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Immunocore, Ltd.
Private Company Edition: Immunocore’s $130m round kicked off a series of $100m-plus venture capital deals, including financings for Xilio, Akouos and Pliant. Also, VC investment in cell and gene therapies surged in 2019 and MPM launched two funds with $126 for early cancer research.
After a record breaking Series A fundraising, the UK biotech hit a series of problems. Can a new CEO and new funding help it fulfil its promise?
Once seen as the champion of biotech start-ups, Woodford’s blind faith has shackled firms to unrealistic valuations.
Melanoma is first target for company developing cancer vaccines and T-cell receptor immunotherapies.
Drug Discovery Tools
- Large Molecule